Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study

  • Wai K. Leung
    Department of Medicine, University of Hong Kong, Hong Kong, China
    Search for articles by this author
  • Hsiu J. Ho
    Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan
    Search for articles by this author
  • Jaw-Town Lin
    School of Medicine, Fu Jen Catholic University, Taipei, Taiwan

    Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan
    Search for articles by this author
  • Ming-Shiang Wu
    Division of Gastroenterology, National Taiwan University Hospital, Taipei, Taiwan
    Search for articles by this author
  • Chun-Ying Wu
    Reprint requests: Professor Chun-Ying Wu, MD, PhD, MPH, Division of Gastroenterology, Taichung Veterans General Hospital, No. 1650, Section 4, Taiwan Avenue, Taichung 407, Taiwan.
    Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan

    Faculty of Medicine and Graduate Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

    Department of Public Health and Graduate Institute of Clinical Medical Sciences, China Medical University, Taichung, Taiwan

    National Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan

    Department of Life Sciences and Rong Hsing Research Center for Translational Medicine, National Chung-Hsing University, Taichung, Taiwan
    Search for articles by this author

      Background and Aims

      The role of prior gastroscopy on the outcome of patients with gastric cancer remains unknown. This study determines the association between intervals of prior gastroscopy and mortality in patients with gastric cancer.


      We identified 20,066 newly diagnosed patients with gastric cancer in the National Health Insurance Database of Taiwan between 2002 and 2007. After we excluded patients who had gastroscopies performed ≤6 months before the diagnosis of cancer, patients were matched into 3 cohorts according to the intervals of prior gastroscopy: 6 months to 2 years (<2 Y cohort), 2 to 5 years (2-5 Y cohort), and none within the previous 5 years (>5 Y cohort). The 3 cohorts were matched for age, curative treatment for gastric cancer, Helicobacter pylori therapy, and propensity scores comprised of sex, comorbidities, and concomitant medication usage. The primary outcome is the hazard ratio (HR) of all-cause mortality.


      After matching, we identified 1286, 1286, and 5144 patients for the <2 Y, 2 to 5 Y, and >5 Y cohorts. Compared with the >5 Y cohort, the HR of all-cause mortality for the <2 Y and 2 to 5 Y cohorts was 0.80 (95% confidence interval [CI], 0.72-0.89; P < .001) and 0.83 (95% CI, 0.76-0.91; P < .001), respectively. The HRs of gastric cancer-specific mortality were significantly lower in the <2 Y (0.80; 95% CI, 0.71-0.91; P < .001) and 2 to 5 Y cohorts (0.83; 95% CI, 0.75-0.93; P < .001).


      Patients with gastric cancer who had a gastroscopy performed within 5 years before the cancer diagnosis had significantly lower mortality. Our results may support the role of repeat endoscopic examination or surveillance endoscopy in selected patients.


      HP (Helicobacter pylori), HR (hazard ratio), NHIRD (National Health Insurance Research Database), RCIPD (Registry for Catastrophic Illness Patient Database)
      To read this article in full you will need to make a payment


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Torre L.A.
        • Bray F.
        • Siegel R.L.
        • et al.
        Global cancer statistics, 2012.
        CA Cancer J Clin. 2015; 65: 87-108
        • Wu C.Y.
        • Lin J.T.
        The changing epidemiology of Asian digestive cancers: from etiologies and incidences to preventive strategies.
        Best Pract Res Clin Gastroenterol. 2015; 29: 843-853
        • Gonzalez C.A.
        • Sala N.
        • Rokkas T.
        Gastric cancer: epidemiologic aspects.
        Helicobacter. 2013; 18: 34-38
        • Leung W.K.
        • Wu M.S.
        • Kakugawa Y.
        • et al.
        Screening for gastric cancer in Asia: current evidence and practice.
        Lancet Oncol. 2008; 9: 279-287
        • Nam J.H.
        • Choi I.J.
        • Cho S.J.
        • et al.
        Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence.
        Cancer. 2012; 118: 4953-4960
        • Wu C.Y.
        • Chen Y.J.
        • Ho H.J.
        • et al.
        Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection.
        JAMA. 2012; 308: 1906-1914
        • Wu C.Y.
        • Kuo K.N.
        • Wu M.S.
        • et al.
        Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
        Gastroenterology. 2009; 137: 1641-1648.e1-2
        • Wu C.Y.
        • Lin J.T.
        • Ho H.J.
        • et al.
        Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study.
        Gastroenterology. 2014; 147: 143-151.e5
        • Wu C.Y.
        • Chan F.K.
        • Wu M.S.
        • et al.
        Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
        Gastroenterology. 2010; 139: 1165-1171
        • Cheng C.L.
        • Kao Y.H.
        • Lin S.J.
        • et al.
        Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.
        Pharmacoepidemiol Drug Saf. 2011; 20: 236-242
        • Wu C.Y.
        • Wu M.S.
        • Kuo K.N.
        • et al.
        Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients.
        J Clin Oncol. 2010; 28: 2952-2957
        • Grambsch P.M.
        • Therneau T.M.
        • Fleming T.R.
        Diagnostic plots to reveal functional form for covariates in multiplicative intensity models.
        Biometrics. 1995; 51: 1469-1482
        • Dan Y.Y.
        • So J.B.
        • Yeoh K.G.
        Endoscopic screening for gastric cancer.
        Clin Gastroenterol Hepatol. 2006; 4: 709-716
        • Gupta N.
        • Bansal A.
        • Wani S.B.
        • et al.
        Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
        Gastrointest Endosc. 2011; 74: 610-624.e2
        • Dinis-Ribeiro M.
        • Areia M.
        • de Vries A.C.
        • et al.
        Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).
        Endoscopy. 2012; 44: 74-94
        • Lassen A.
        • Hallas J.
        • de Muckadell O.B.
        The risk of missed gastroesophageal cancer diagnoses in users and nonusers of antisecretory medication.
        Gastroenterology. 2005; 129: 1179-1186
        • Menon S.
        • Trudgill N.
        How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis.
        Endosc Int Open. 2014; 2: E46-E50
        • Yamada H.
        • Ikegami M.
        • Shimoda T.
        • et al.
        Long-term follow-up study of gastric adenoma/dysplasia.
        Endoscopy. 2004; 36: 390-396
        • de Vries A.C.
        • van Grieken N.C.
        • Looman C.W.
        • et al.
        Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands.
        Gastroenterology. 2008; 134: 945-952
        • Lee T.Y.
        • Wang R.C.
        • Lee Y.C.
        • et al.
        The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: a long-term cohort study.
        J Clin Gastroenterol. 2016; 50: 532-537
        • Meimarakis G.
        • Winter H.
        • Assmann I.
        • et al.
        Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study.
        Lancet Oncol. 2006; 7: 211-222
        • Marrelli D.
        • Pedrazzani C.
        • Berardi A.
        • et al.
        Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer.
        Cancer. 2009; 115: 2071-2080
        • Fukase K.
        • Kato M.
        • Kikuchi S.
        • et al.
        Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
        Lancet. 2008; 372: 392-397